Galderma wins China approval for Relfydess after positive Phase 3 frown line results. Competition and its pending US review remain crucial.
Foresee's CAMCEVI 42 mg wins China approval for advanced prostate cancer. Examine GeneScience's launch plans, clinical evidence and licensing economics.
Chipscreen secures China IND clearance for CS43158, targeting FLT3 mutations and resistance pathways in acute myeloid leukemia.
Akeso starts Phase III cadonilimab testing in colon cancer, with 386 patients planned and recurrence outcomes central to its clinical strategy.
Norroy Bioscience has started pivotal Phase 3 development of 177Lu-NYM032 in PSMA-positive metastatic castration-resistant prostate cancer, with a registered target enrollment of about 600 patients and overall survival as the primary objective.
HBM7004 can now enter clinical development in both China and the United States after NMPA and FDA IND clearances, putting Harbour BioMed’s B7H4-dependent T-cell engager into its first human test.
China has cleared Akeso’s AK157D1 for Phase 1 testing in advanced solid tumors, adding a DXd-class B7-H3 programme to a target already attracting late-stage ADC competition.
China’s Center for Drug Evaluation has accepted opamtistomig for previously treated advanced EP-NEC and placed the application under Priority Review, while detailed pivotal data await presentation.
Belenos says BEL512 met all Phase 2 CRSwNP endpoints, but undisclosed effect sizes make the planned 2027 Phase 3 trial the critical test.
NCX 470 enters China regulatory review after two positive Phase 3 glaucoma trials. Read why U.S. and China decisions could reshape Nicox.